Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards
PLOS Digital Health · 07.06.2023 · 2 (6) · e0000054
DOI: 10.1371/journal.pdig.0000054 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Digital Health, online erschienen am 07.06.2023. Verfasst von Yasemin Ural und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Uro-Oncology and robot assisted surgery, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Certified Cancer Centers must present all patients in multidisciplinary tumor boards (MTB), including standard cases with well-established treatment strategies. Too many standard cases can absorb much of the available time, which can be unfavorable for the discussion of complex cases. In any case, this leads to a high quantity, but not necessarily a high quality of tumor boards. Our aim was to develop a partially algorithm-driven decision support system (DSS) for smart phones to provide evidence-based recommendations for first-line therapy of common urological cancers. To assure quality, we compared each single digital decision with recommendations of an experienced MTB and obtained the concordance.1873 prostate cancer patients presented in the MTB of the urological department of the University Hospital of Cologne from 2014 to 2018 have been evaluated. Patient characteristics included age, disease stage, Gleason Score, PSA and previous therapies. The questions addressed to MTB were again answered using DSS. All blinded pairs of answers were assessed for discrepancies by independent reviewers. Overall concordance rate was 99.1% (1856/1873). Stage specific concordance rates were 97.4% (stage I), 99.2% (stage II), 100% (stage III), and 99.2% (stage IV). Quality of concordance were independent of age and risk profile. The reliability of any DSS is the key feature before implementation in clinical routine. Although our system appears to provide this safety, we are now performing cross-validation with several clinics to further increase decision quality and avoid potential clinic bias.
Autor:innen und Institutionen
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Uro-Oncology and robot assisted surgery, Germany.
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany.
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of General, Visceral, Cancer and Transplantation Surgery, Germany.
ORCID-Profile: Yasemin Ural, Thomas Elter, Rabi Raj Datta
Zitieren
APA
Ural, Y., Elter, T., Yilmaz, Y., Hallek, M., Datta, R. R., Kleinert, R., Heidenreich, A., & Pfister, D. (2023). Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards. PLOS Digital Health, 2(6), e0000054. https://doi.org/10.1371/journal.pdig.0000054
Vancouver
Ural Y, Elter T, Yilmaz Y, Hallek M, Datta RR, Kleinert R, et al. Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards. PLOS Digital Health. 2023;2(6):e0000054. doi:10.1371/journal.pdig.0000054
BibTeX
@article{Ural2023,
author = {Ural, Yasemin and Elter, Thomas and Yilmaz, Yasemin and Hallek, Michael and Datta, Rabi Raj and Kleinert, Robert and Heidenreich, Axel and Pfister, David},
title = {Validation and implementation of a mobile app decision support system for prostate cancer to improve quality of tumor boards},
journal = {PLOS Digital Health},
year = {2023},
volume = {2},
number = {6},
pages = {e0000054},
doi = {10.1371/journal.pdig.0000054}
}
EUVIMED